I usædvanlige tilfælde er der rapporteret om interstitiel lungesygdom (ILD) - lignende hændelser, inklusive dødsfald, hos patienter, som modtog Tarceva som behandling af ikke- småcellet lungecancer (NSCLC), pancreas- cancer eller andre fremskredne solide tumorer.
Cases of interstitial lung disease (ILD)-like events, including fatalities, have been reported uncommonly in patients receiving Tarceva for treatment of non-small cell lung cancer (NSCLC), pancreatic cancer or other advanced solid tumours.